What Is Motilin? The Hormone That Cleans the Gut Between Meals

Guides · Gut hormones

Motilin is a 22-amino-acid gut hormone that does its work when you are not eating: it triggers the sweeping wave of contractions that clears the stomach and small intestine between meals. It is also one of the best examples in physiology of how much a research field can be held back by an accident of evolution. Mice and rats lost the motilin system entirely, and fifty years of drug development has struggled ever since.

What is motilin?

Motilin is encoded by the MLN gene and stored in UniProt as P12872. The precursor is trimmed to a mature 22-residue peptide of roughly 2,700 daltons, catalogued in PubChem with the molecular formula C120H188N34O35S. It was isolated and purified from hog duodenal mucosa by J. C. Brown and colleagues in the early 1970s, and it was named for exactly what they observed it doing: stimulating gastric motor activity.

It is made by enteroendocrine cells – usually called Mo cells – in the mucosa of the duodenum and proximal jejunum, with a few in the ileum. Notably, none are found in the stomach, colon or rectum, despite the fact that motilin’s most famous action happens in the stomach.

The housekeeping wave

Between meals the gut does not sit idle. It runs a repeating cycle called the migrating motor complex, which sweeps from the stomach down the small intestine roughly every 90 to 120 minutes in humans and dogs. It is usually described in three phases, with some authors adding a brief fourth: a quiescent phase with almost no contractions, a phase of irregular low-amplitude activity, then a short burst of regular high-amplitude contractions, and finally a quick transition back to quiet.

That third phase is the interesting one. Plasma motilin cycles in step with it, peaking as the burst of gastric origin begins, and giving motilin to humans or dogs produces gastric phase III contractions. The evidence that the duodenum is the source is direct: after duodenectomy in dogs, gastric phase III disappears and plasma motilin stops fluctuating.

The mechanism is not simply motilin squeezing muscle. Motilin-induced gastric phase III is blocked by 5-HT3 antagonists in both dogs and humans, which points to mucosal serotonin release and a vagal reflex arc rather than a purely local action. Motilin appears to act on enteric neurons, smooth muscle and vagal afferents.

Functionally, the complex is housekeeping. It moves undigested residue along, helps carry bacteria from the small intestine toward the large, and limits bacterial migration back up into the terminal ileum. Eating abolishes it: gastric distension and nutrients in the duodenum replace the fasting pattern with a fed one and suppress motilin release. Motilin has also been linked to the sensation of hunger between meals, though that is a more recent and narrower literature than the equivalent story for ghrelin.

Motilin and ghrelin: sister systems

The motilin receptor, MLNR, spent years as an orphan called GPR38 before it was matched to motilin in 1999. Ghrelin’s receptor was identified around the same time, and the two turned out to be close relatives: they share roughly 52 percent of their amino acids overall and about 86 percent across the transmembrane regions. Motilin and ghrelin are themselves structurally related, and in the human small intestine they are co-secreted from the same prominent population of endocrine cells.

What they do not do is cross over. Ghrelin does not bind the motilin receptor and motilin does not bind the ghrelin receptor; differences at the N-terminus keep them separate. This is a useful counterexample to the assumption that structurally similar peptides in the same family will show meaningful cross-reactivity.

MLNR is a class A G-protein-coupled receptor. IUPHAR lists its principal transduction as Gq/G11 with G12/G13 also recorded, and the two cryo-EM structures published in 2023 – one with motilin bound, one with erythromycin – are of the Gq-coupled receptor. Downstream it runs through phospholipase C, IP3 and a rise in intracellular calcium. No constitutive activity has been detected, which distinguishes it from its ghrelin-receptor cousin.

The rodent problem

Here is the fact that explains most of this field’s history. Laboratory rodents do not have a working motilin system. The Guide to Pharmacology states it plainly: the gene encoding the motilin precursor is absent in laboratory rodents, and the receptor appears to be a pseudogene.

The loss happened in stages. Comparative genomics indicates the receptor gene was inactivated first, apparently very early in rodent evolution, and the peptide gene was then lost separately – once in the guinea pig lineage and again in the common ancestor of mouse and rat. The kangaroo rat still carries an intact motilin reading frame, but its receptor is non-functional, so the system does not work there either.

The consequence for research is severe. The standard animal used to screen gastrointestinal drugs simply cannot report on motilin pharmacology. Investigators have had to work in dogs, in the house musk shrew, or in transgenic mice engineered to express the human motilin receptor. Scattered reports of motilin or macrolide effects in ordinary rodents do exist, and their mechanism is described in the literature as obscure.

Erythromycin, the antibiotic that is also a motilin agonist

Erythromycin’s gastrointestinal cramping had long been a nuisance side effect before anyone knew why. In 1984 Itoh and colleagues showed that intravenous erythromycin in dogs produced strong gastric and duodenal contractions that migrated to the terminal ileum and closely resembled naturally occurring interdigestive contractions. The macrolide was acting at the motilin receptor – which remains, as far as the receptor databases record, the first GPCR reported to be activated by a class of antibiotics.

That pharmacology has two consequences. It explains the nausea, cramping and occasional vomiting associated with macrolides, which are on-target effects rather than a mystery. And it gave clinicians an off-label prokinetic: erythromycin is used in gastroparesis and given before endoscopy in upper gastrointestinal bleeding to clear blood from the stomach and improve visualisation, the latter as a conditional recommendation resting on very-low-quality evidence.

Two caveats matter. Erythromycin is less potent than motilin itself, and the response fades quickly. Guidelines recommend limiting macrolide prokinetic courses to roughly one to four weeks because of tachyphylaxis, and desensitisation of the human motilin receptor by motilides has been characterised directly – a textbook case of the phenomenon we cover in tachyphylaxis versus tolerance versus downregulation. Erythromycin is not FDA-approved for any prokinetic indication; its labelling covers antibacterial use only.

The motilide graveyard

Several purpose-built motilin receptor agonists, collectively called motilides, have reached patients. None has been approved.

The most instructive is ABT-229. In a trial of 270 patients with type 1 diabetes and postprandial symptoms, it was not effective – and bloating, postprandial nausea, epigastric discomfort, heartburn and acid regurgitation all worsened in a dose-dependent fashion compared with placebo. A drug designed to speed up gastric emptying made symptoms worse. The explanations offered in the literature are hypotheses rather than settled facts: motilin agonists raise proximal gastric tone and may aggravate impaired fundic accommodation, and rapid tachyphylaxis may blunt any benefit.

Mitemcinal, an orally active acid-resistant non-macrolide agonist, was negative in the overall diabetic gastropathy population, with a positive signal confined to a healthier subgroup. Camicinal, a selective small-molecule agonist, went through Phase 2 in diabetic gastroparesis, critical illness and Parkinson’s disease and has not been approved anywhere.

The class-level lesson is one the field has stated openly: accelerating gastric emptying is not the same as relieving symptoms, and the correlation between transit measurements and how patients actually feel is weak. Whether biased agonism at the motilin receptor could separate benefit from nausea and tachyphylaxis remains an open question. As of August 2026, no motilin receptor agonist has been approved by the FDA, and metoclopramide remains the only FDA-approved drug for gastroparesis in the United States.

What is still unresolved

More than fifty years after motilin was purified, the mechanism of the migrating motor complex is still described in the literature as unclear. Open questions include whether the motilin rise causes gastric phase III or reports it, where exactly the receptors mediating it sit, what starts and stops each cycle, and why duodenal phase III often precedes gastric phase III. There is also a feedback puzzle: giving motilin stimulates further endogenous motilin release, which implies some braking mechanism nobody has identified.

Species variability is a broader problem than the rodent gap alone. Dog and human receptors differ enough to shift ligand affinities, chicken motilin does not mediate gastric phase III, and zebrafish motilin activates its receptor without contracting gut tissue. The 2023 cryo-EM structures of the receptor bound to motilin and to erythromycin are the field’s genuine recent advance, because they finally give structure-based design something to work with.

Frequently asked questions

Is motilin the same as ghrelin?

No. They are related peptides acting at related receptors, but they do not activate each other’s receptors, and their roles differ: motilin drives the fasting housekeeping wave, while ghrelin drives growth hormone release and appetite before meals.

Why is an antibiotic used as a gut motility drug?

Because erythromycin happens to be an agonist at the motilin receptor, an activity discovered by working backwards from its gastrointestinal side effects. It is used off-label for that purpose; it is not FDA-approved for it, and the effect fades within weeks.

Is motilin available as a research peptide or a treatment?

Motilin itself is not an approved drug and is not available as a therapy. No motilin receptor agonist has been approved by the FDA for any motility indication. This page is informational and does not describe a treatment.

Why did drugs that speed up the stomach fail in gastroparesis?

The clearest answer comes from ABT-229, which accelerated emptying and made symptoms worse. Symptoms in gastroparesis and functional dyspepsia correlate weakly with measured transit, so a drug can succeed on the physiological endpoint and fail on the one that matters to patients.

Informational only – not medical advice · 21+. VialHelp does not sell peptides and does not recommend any product, brand or protocol. Off-label uses described here are reported for context and are not recommendations.